aFGF Injection for Nerve Regeneration in Compression Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nerve compressive syndrome, such as decompression surgery, often fail to fully recover nerve function and may lead to prolonged recovery times and persistent symptoms due to the inability to repair degenerated nerve fibers.
Innovation Solution
Administration of human acidic fibroblast growth factor (aFGF) through intraneural, intramuscular, or foramen magnum injection, potentially combined with fibrin glue for sustained release, to promote neural regeneration and functional recovery in nerve compression syndrome and entrapment neuropathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If decompression surgery is performed to remove compressive source, then pressure is released and neuropathic pain is mitigated, but nerve fiber degeneration cannot be repaired and functional recovery is incomplete
Solution Approach 1:
The patent introduces acidic fibroblast growth factor (aFGF) as an intermediary substance that bridges the gap between decompression surgery and complete nerve recovery. aFGF is administered via injection to promote nerve fiber regeneration and functional recovery, serving as a mediating agent that enhances the effectiveness of decompression surgery without replacing it.
Solution Approach 2:
The patent changes the therapeutic parameter from purely mechanical decompression to a combination of decompression and biological modulation. By introducing aFGF, the treatment shifts from removing compressive forces alone to actively promoting nerve regeneration, thereby improving the reliability of functional recovery while maintaining pain relief.
2Object-affected harmful factors
If decompression surgery is performed, then compressive source is removed, but recovery time is prolonged and symptoms may persist
Solution Approach 1:
The patent applies preliminary action by administering aFGF injection in conjunction with or following decompression surgery to initiate nerve regeneration processes early in the recovery timeline. This preliminary biological intervention accelerates the natural recovery process, reducing the overall recovery time and preventing persistent symptoms.
Solution Approach 2:
The patent ensures continuity of useful action by combining decompression surgery with ongoing aFGF administration. This continuous approach maintains therapeutic effectiveness throughout the recovery period, ensuring that nerve regeneration proceeds continuously rather than in discrete phases, thereby reducing total recovery time.
3Strength
If traditional decompression surgery is used, then structural compression is relieved, but neural regeneration is not promoted
Solution Approach 1:
The patent merges two previously separate approaches: decompression surgery for structural relief and aFGF injection for neural regeneration. By combining these treatments into a unified therapeutic protocol, the patent achieves both immediate structural decompression and active neural regeneration, thereby improving overall productivity of the treatment.
Solution Approach 2:
The patent creates a composite treatment approach that integrates mechanical decompression with biological regeneration agents. This composite therapy combines the structural benefits of surgery with the regenerative properties of aFGF, achieving synergistic effects that improve both structural relief and neural regeneration capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
aFGF treatment demonstrates significant improvement in neural function recovery compared to traditional decompression surgery, as evidenced by enhanced grasping power tests in animal models, indicating a safer and more effective approach for nerve regeneration.
Implementation Method 1
acid fibroblast growth factor (aFGF) plays a critical role in neural regeneration
Data Source
Figure 1
AI summary
The present invention provides the method for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy, comprising administering human acidic fibroblast growth factor (aFGF) to a subject in need thereof.